Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tolbutamide × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Rituximab 1238 Cyclophosphamide 1164 Vincristine 593 Doxorubicin 530 Etoposide 473 Prednisone 455 Cytarabine 426 fludarabine 410 Methotrexate 382 Dexamethasone 362 fludarabine phosphate 349 Lenalidomide 312 Filgrastim 310 Radiotherapy 244 Bendamustine Hydrochloride 243 venetoclax 229 ibrutinib 222 Melphalan 207 obinutuzumab 203 Peripheral Blood Stem Cell Transplantation 203 Granulocyte Colony-Stimulating Factor 181 Gemcitabine 181 Bortezomib 177 Whole-Body Irradiation 164 Busulfan 164 Mycophenolic Acid 153 Tacrolimus 135 Calcium Dobesilate 130 Specimen Handling 129 Ifosfamide 127

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01185548 2018-10-19

JZAR

Eli Lilly and Company

Phase 1 Terminated

4 enrolled 8 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡